(PharmaNewsWire.Com, July 19, 2017 ) RNA interference is a process in which RNA inhibits the gene expression, by neutralizing mRNA molecules. It is also called Gene silencing. Recently, we are sending manmade drugs to carry out these functions and that process is called RNAi Drug Delivery.
RNAi drugs are used to cure various chronic diseases genetically. Right now research is going on to find the right genes which causes cancer and to find its respective RNAi Drug. This method is developing rapidly from past few years.
Few factors like Increasing incidence of chronic diseases like cancer and cardiovascular diseases, and innovative Applications of drug delivery market are driving this market. In addition, Research carried out in RNA Therapeutic field has also fueled the growth in Europe RNA Drug Delivery Market. But, High investment and stringent regulations are some of the major restraints to this market. Targeted Delivery of RNAi Drugs is the key challenge faced by the market.
Europe RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into aptamer drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology and nanoparticle drug delivery technology. Based on Therapeutic Application, the market is further segmented into cardiology, metabolic disorders, oncology, ophthalmology, infectious diseases and neurology.
Based on Geography, Europe is further segmented into UK, Germany, Italy, France and Spain. This region holds the second highest Share in the Global market because of their advanced research facilities and presence of major players in this region.
Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
